Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 13.36 as of 2026-09-15T14:45:31.786Z.
Consensus retrieved: 2026-09-13T22:22:55.543Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-09-15T14:45:31.786Z.
Quote observation: 2026-09-15T14:45:14.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 4d0dd03ce25408bf7ac658d648b2d5a2e9572817b3796d023b4e65a6fbfd6d64
Forward PE Ratio (13.36) = Dated Quote Price ($43.93) / Consensus Forward EPS ($3.29)
FORWARD PE RATIO
13.36
SECTOR MEDIAN · HEALTHCARE
19.22
median of 76 covered companies
CURRENT VS SECTOR MEDIAN
-30.49%
vs the sector median at left
Boston Scientific Corporation
Market Cap
$65.30B
Forward PE Ratio
13.36
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Boston Scientific Corporation (BSX) | $65.30B | 13.36 |
| Cencora, Inc. (COR)vs › | $62.65B | 18.01 |
| Moderna, Inc. (MRNA)vs › | $56.67B | N/A |
| Cardinal Health, Inc. (CAH)vs › | $54.60B | 18.58 |
| Cigna Corporation (CI)vs › | $76.17B | 9.45 |
| Regeneron Pharmaceuticals, Inc. (REGN)vs › | $80.05B | 14.25 |
| Becton, Dickinson and Company (BDX)vs › | $50.32B | 14.41 |
| Edwards Lifesciences Corporation (EW)vs › | $49.19B | 28.46 |
| Humana Inc. (HUM)vs › | $47.72B | 43.42 |
| Teva Pharmaceutical Industries Limited (TEVA)vs › | $44.73B | 19.33 |
Trailing P/E
17.9
reported TTM EPS
Forward P/E
13.4
consensus EPS · fiscal year ending 2026-12-31
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $3.29 implies +33.7% EPS growth vs the reported trailing $2.46.
At the dated quote price of $43.93, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $3.29 | $3.18 – $3.36 | 15 | 13.4x |
| 2027-12-31 | $3.42 | $3.32 – $3.71 | 16 | 12.9x |
| 2028-12-31 | $3.79 | $3.61 – $4.09 | 7 | 11.6x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
